Compare Novartis AG (NVS) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs VNET Group Inc — how do they compare? Novartis AG trades at $143.31 (market cap $268.57B), while VNET Group Inc trades at $5.48 (market cap $1.47B). The key difference: Novartis AG is far larger — about 182.7× VNET Group Inc's market cap, and Novartis AG pays a 3.31% dividend while VNET Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and VNET Group Inc for 16 Days on average.
| NVS | VNET | |
|---|---|---|
Market Cap | $268.57B | $1.47B |
Volume | 1,532,573 | 4,955,295 |
Sector | Health | Technology |
52-Week High | $168.62 | $14.03 |
52-Week Low | $121.80 | $5.13 |
Typical Hold Time | 82 Days | 16 Days |
Enterprise Value | $309.89B | $5.04B |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
VNET trades at $5.46, up 1.3% today but near 52-week lows, with a bearish technical signal. The company reported a net loss of $256.77 million in 2025, with a negative net income margin of -22.18%, though revenue grew to $9.95 billion. Recent news includes a strategic investment closing and a cooperation agreement with CATL, providing some positive catalysts amid financial challenges.
The outlook remains cautious due to persistent losses and high leverage, but analyst sentiment is moderately bullish with 62.5% buy ratings. Key risks include balance sheet strain from negative cash flow and competitive pressures in the data center market. Upside potential hinges on execution of new partnerships and demand for AI infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
